CAMBRIDGE, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced that findings with four compounds now in clinical testing will be reported at the American Society of Hematology (ASH) annual meeting to be held in Atlanta, GA, December 8-11, 2007.
